Célia Aparecida de Paula Roesler

Célia Aparecida de Paula Roesler

Auto-generated profile, based on publicly available information

Célia Aparecida de Paula Roesler

Centro Médico de Neurologia, São Paulo SP, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
FKFernando Kowacs
Fernando Kowacs
CRCélia Aparecida de Paula Roesler
Célia Aparecida de Paula Roesler
EPElcio Piovesan
Elcio Piovesan
ESElder Machado Sarmento
Elder Machado Sarmento
HCHenrique Carneiro de Campos
Henrique Carneiro de Campos
MJMauro Eduardo Jurno
Mauro Eduardo Jurno
Chronic migraine poses a significant personal, social and economic burden and is characterized by headache present on 15 or more days per month for at least three months, with at least eight days of migrainous headache per month. It is frequently associated with analgesic or acute migraine medication overuse and this should not be overlooked. The present consensus was elaborated upon by a group of members of the Brazilian Headache Society in order to describe current evidence and to provide recommendations related to chronic migraine pharmacological and nonpharmacological treatment. Withdrawal strategies in medication overuse headache are also described, as well as treatment risks during pregnancy and breastfeeding. Oral topiramate and onabotulinum toxin A injections are the only treatments granted Class A recommendation, while valproate, gabapentin, and tizanidine received Class B recommendation, along with acupuncture, biofeedback, and mindfulness. The anti-CGRP or anti-CGRPr monoclonal antibodies, still unavailable in Brazil, are promising new drugs already approved elsewhere for migraine prophylactic treatment, the efficacy of which in chronic migraine is still to be definitively proven.

1 August 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
EMEliana Meire Melhado
Eliana Meire Melhado
PSPaulo Sergio Faro Santos
Paulo Sergio Faro Santos
AKAlexandre Ottoni Kaup
Alexandre Ottoni Kaup
ACAline Turbino Neves Martins da Costa
Aline Turbino Neves Martins da Costa
CRCélia Aparecida de Paula Roesler
Célia Aparecida de Paula Roesler
YFYara Dadalti Fragoso
Yara Dadalti Fragoso
The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.

1 September 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
PSPaulo Sergio Faro Santos
Paulo Sergio Faro Santos
EMEliana Meire Melhado
Eliana Meire Melhado
AKAlexandre Ottoni Kaup
Alexandre Ottoni Kaup
ACAline Turbino Neves Martins da Costa
Aline Turbino Neves Martins da Costa
CRCélia Aparecida de Paula Roesler
Célia Aparecida de Paula Roesler
YFYara Dadalti Fragoso
Yara Dadalti Fragoso
Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder.Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience.Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy.Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease.Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.

1 March 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
FKFernando Kowacs
Fernando Kowacs
CRCélia Aparecida de Paula Roesler
Célia Aparecida de Paula Roesler
RSRaimundo Pereira Silva-Néto
Raimundo Pereira Silva-Néto
Since then, even though the expression “migrânea” is absent from Brazilian dictionaries and from the Vocabulário Ortográfico da Língua Portuguesa (Portuguese Language Orthographic Vocabulary, a Brazilian Portuguese lexicon published by the Academia Brasileira de Letras)6, it was maintained in the official translations of both the second and the third editions of the International Classification of Headache Disorders7,8.